ViewRay (NASDAQ:VRAY) was downgraded by investment analysts at ValuEngine from a “hold” rating to a “sell” rating in a research report issued on Friday.
Several other equities research analysts also recently issued reports on the stock. Mizuho reiterated a “buy” rating and set a $12.00 price objective on shares of ViewRay in a research note on Wednesday, October 25th. Northland Securities reiterated a “buy” rating and set a $10.00 price objective on shares of ViewRay in a research note on Friday, November 17th. One equities research analyst has rated the stock with a sell rating and five have given a buy rating to the stock. ViewRay currently has a consensus rating of “Buy” and an average price target of $10.60.
Shares of ViewRay (NASDAQ:VRAY) opened at $9.90 on Friday. The company has a quick ratio of 1.20, a current ratio of 1.59 and a debt-to-equity ratio of -1.67. ViewRay has a 52 week low of $3.01 and a 52 week high of $10.39.
Hedge funds have recently made changes to their positions in the company. Nationwide Fund Advisors boosted its stake in shares of ViewRay by 843.2% in the second quarter. Nationwide Fund Advisors now owns 16,543 shares of the company’s stock valued at $107,000 after purchasing an additional 14,789 shares during the period. HighTower Advisors LLC boosted its stake in shares of ViewRay by 5.0% in the second quarter. HighTower Advisors LLC now owns 21,000 shares of the company’s stock valued at $135,000 after purchasing an additional 1,000 shares during the period. UBS Group AG boosted its stake in shares of ViewRay by 447.7% in the first quarter. UBS Group AG now owns 22,479 shares of the company’s stock valued at $192,000 after purchasing an additional 18,375 shares during the period. The Manufacturers Life Insurance Company purchased a new position in shares of ViewRay in the second quarter valued at $159,000. Finally, White Pine Capital LLC purchased a new position in shares of ViewRay in the second quarter valued at $173,000. Institutional investors and hedge funds own 50.08% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This story was originally posted by Community Financial News and is owned by of Community Financial News. If you are viewing this story on another domain, it was copied illegally and republished in violation of U.S. & international copyright & trademark legislation. The original version of this story can be viewed at https://www.com-unik.info/2017/12/03/viewray-vray-rating-lowered-to-sell-at-valuengine.html.
ViewRay Company Profile
ViewRay, Inc designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered.
What are top analysts saying about ViewRay Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for ViewRay Inc. and related companies.